One in 3 high blood pressure patients failing to take medication

One in three people who suffer from high blood pressure are failing to take medication as prescribed by their healthcare professionals, a new study led by the University of Leicester has suggested. A study on 1,400 hypertensive patients, conducted in collaboration between the Universities of Leicester (lead authors Dr Pankaj Gupta, Dr Prashanth Patel from the Department of Cardiovascular Sciences at the University of Leicester), Manchester (Prof M Tomazweski) and Czech Republic (Prof J Widimsky) has used a novel urine test to find that non-adherence to prescribed medications is around 30-40%.

Non-adherence to medications has been known since the time of Hippocrates and has been found to be one of the important reasons for the lack of blood pressure control in at least 50% of the patients in the study - despite the availability of good medicines.

Non-adherence leads to poorer cardiovascular outcomes and is thought to cost $100 billion to the US health economy.

A crucial reason for the lack of progress in improving adherence has been the previous lack of a clinically useful objective measure to show when people are not taking their prescribed medicine.

The research team has worked to develop a robust and reliable biochemical screening method to assess for non-adherence to antihypertensive medications in urine or blood using a technique called liquid chromatography-tandem mass spectrometry.

The team has set up a National Centre for Adherence Testing (NCAT, This email address is being protected from spambots. You need JavaScript enabled to view it.) at Leicester's Hospitals and receive samples from around 25 hypertension clinics across UK.

The study showed that more than 41.6% of the UK cohort and 31.5% of the Czech cohort were non-adherent to their anti-hypertensive medications.

Moreover 14.5% of the UK and 12% of the Czech cohort were not taking any medications. Crucially non-adherence was related to the number of prescribed medications with the risk increasing by >75% with each increase in medication and it was highest with diuretics.

As well as the above, younger patients and females were found to have an increased risk of non-adherence to prescribed medications.

Dr Gupta said: "Given the high prevalence of non-adherence, we should assess patients, particularly those on multiple antihypertensive medications or those who do not have an expected response to treatment"

Dr Patel said: "This is a simple, relatively inexpensive and a robust test. It and has anecdotally changed the management of hypertension in many centres who use the test."

The researchers hope to ascertain whether non-adherent patients, on follow up, improved their medication taking behaviour and if adherence testing led to an improvement in blood pressure.

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M.
Risk Factors for Nonadherence to Antihypertensive Treatment.
Hypertension. 2017 Jun;69(6):1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729.

Most Popular Now

FDA approves Vosevi for Hepatitis C

The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mil...

Green tea ingredient may ameliorate memory impairm…

A study published online in The FASEB Journal, involving mice, suggests that EGCG (epigallocatechin-3-gallate), the most abundant catechin and biologically active compone...

New way found to boost immunity in fight cancer an…

An international research team led by Université de Montréal medical professor Christopher Rudd, director of research in immunology and cell therapy at Maisonneuve-Rosemo...

Amgen and Array BioPharma announce preclinical lic…

Amgen (NASDAQ:AMGN) and Array BioPharma (NASDAQ:ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders...

Merck and Pfizer collaborate with Corning

Merck (NYSE: MRK), Pfizer (NYSE: PFE) and Corning Incorporated (NYSE: GLW) today announced collaborations that have enabled the modernization of pharmaceutical packaging ...

One minute of running per day associated with bett…

A single minute of exercise each day is linked to better bone health in women, new research shows. Scientists from the University of Exeter and the University of Leiceste...

Americans say discussions about clinical trials sh…

An overwhelming majority of Americans (86%) agree that health care professionals should discuss clinical trials with patients diagnosed with a disease as part of their st...

AstraZeneca and Merck establish strategic oncology…

AstraZeneca and Merck & Co., Inc., (Merck; known as MSD outside of the US and Canada) today announced that they have entered a global strategic oncology collaboration to ...

27 Phase III and 8 Phase II Alzheimer's drugs on t…

Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years, according to a revised Alzheime...

Johnson & Johnson announces encouraging first-…

Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Compani...

How physical exercise prevents dementia

Numerous studies have shown that physical exercise seems beneficial in the prevention of cognitive impairment and dementia in old age. Now researchers at Goethe Universit...

New drug may treat and limit progression of Parkin…

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]